Platinum Sensitivity in <i>IDH1/2</i> Mutated Intrahepatic Cholangiocarcinoma: Not All "BRCAness" Is Created Equal.

Doroshow, Deborah Blythe; Wei, Wei; Mehrotra, Meenakshi; Sia, Daniella; Eder, Joseph Paul; Bindra, Ranjit; Houldsworth, Jane; LoRusso, Patricia; Walther, Zenta

Platinum Sensitivity in IDH1/2 Mutated Intrahepatic Cholangiocarcinoma: Not All "BRCAness" Is Created Equal.

Doroshow, Deborah Blythe; Wei, Wei; Mehrotra, Meenakshi; Sia, Daniella; Eder, Joseph Paul; Bindra, Ranjit; Houldsworth, Jane; LoRusso, Patricia; Walther, Zenta.

Affiliation

Doroshow DB; Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA.
Wei W; Yale School of Public Health, New Haven, CT, USA.
Mehrotra M; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Sia D; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Eder JP; Yale School of Medicine, New Haven, CT, USA.
Bindra R; Yale Cancer Center, New Haven, CT, USA.
Houldsworth J; Yale Cancer Center, New Haven, CT, USA.
LoRusso P; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Walther Z; Yale School of Medicine, New Haven, CT, USA.

Cancer Invest ; 41(7): 646-655, 2023 Sep.

Article de En | MEDLINE | ID: mdl-37505929

Sujet(s)
Mots clés

Cholangiocarcinoma; DNA damage repair; isocitrate dehydrogenase; platinum sensitivity

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs des canaux biliaires / Cholangiocarcinome Type d'étude: Clinical_trials / Diagnostic_studies / Observational_studies Limites: Humans Langue: En Journal: Cancer Invest Année: 2023 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google